Zai Lab Limited reported that authorised capital remained at 5 billion ordinary shares with a par value of USD 0.000006 each, equivalent to USD 30,000, as of 31 May 2026. No changes occurred during the month.

The issued share base stayed flat at 1.13 billion ordinary shares, and the company continued to hold no treasury shares. Zai Lab confirmed compliance with the Main Board’s 25% minimum public-float requirement; 401.42 million of the issued ordinary shares are held as American Depositary Shares.

Equity incentive activity was concentrated in option exercises and re-balancing:

• 4.64 million options under the 2015 Equity Incentive Plan and 0.03 million options under the 2022 Plan were exercised, all settled with existing shares. • The exercises generated USD 0.41 million in proceeds without increasing the total share count. • After lapses and exercises, outstanding options stood at 0.14 million (2015 Plan), 27.42 million (2017), 31.35 million (2022) and 17.07 million (2024). The 2024 Plan also saw 1.37 million new options granted during the month.

Restricted and performance share units (RSUs/PSUs) moved as follows:

• RSU grants under the 2024 Plan added 0.75 million units. • Cumulative lapses across the 2017, 2022 and 2024 plans totaled 1.76 million units, while vested RSUs reached 0.21 million, all settled with existing shares. • Outstanding unvested equity now comprises 3.23 million RSUs (2017), 5.45 million RSUs (2022), 14.24 million RSUs (2024) and 2.40 million PSUs (2024).

There were no warrants, convertibles or other share-linked instruments in issue, and no repurchases or treasury-share movements occurred. The company affirmed that all equity transactions complied with Hong Kong listing rules and other applicable regulations.